North China Pharmaceutical Co (SHSE:600812) Additional Paid-In Capital : ¥0 Mil(As of Mar. 2024)

View and export this data going back to 1994. Start your Free Trial

What is North China Pharmaceutical Co Additional Paid-In Capital?

North China Pharmaceutical Co's quarterly additional paid-in capital increased from Sep. 2023 (¥0 Mil) to Dec. 2023 (¥3,879 Mil) but then stayed the same from Dec. 2023 (¥3,879 Mil) to Mar. 2024 (¥0 Mil).

North China Pharmaceutical Co's annual additional paid-in capital increased from Dec. 2021 (¥3,879 Mil) to Dec. 2022 (¥3,879 Mil) but then stayed the same from Dec. 2022 (¥3,879 Mil) to Dec. 2023 (¥3,879 Mil).

North China Pharmaceutical Co Additional Paid-In Capital Historical Data

The historical data trend for North China Pharmaceutical Co's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

North China Pharmaceutical Co Additional Paid-In Capital Chart

North China Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

3,443.91

3,898.13

3,879.12

3,879.37

North China Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															-	3,879.37	-	3,879.37	-

North China Pharmaceutical Co Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

North China Pharmaceutical Co Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of North China Pharmaceutical Co's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

North China Pharmaceutical Co (SHSE:600812) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » North China Pharmaceutical Co Ltd (SHSE:600812) » Definitions » Additional Paid-In Capital

Traded in Other Exchanges

N/A

Address

No. 388 Heping East Road, Shijiazhuang, Hebei, CHN, 050015

Website

http://www.ncpc.com

North China Pharmaceutical Co Ltd is engaged in the manufacture and sale of antibiotics, vitamins, and pharmaceutical products in China. The main products include antibiotics such as penicillin, vitamins, cephalosporins, streptomycin, biotechnological drugs, new preparations, and biological products.

Executives

Gao Ren Long	senior management
Lian Fa Zhe	Director

North China Pharmaceutical Co (SHSE:600812) Headlines

No Headlines